Replies to post #120665 on Amarin Corp Plc (AMRN)

[Biobillionair]

Then Amarin needs a ton of cash to start promoting off-label immediately...$79 million isn’t even close to what we need. Amarin has to be prepared to litigate R-I label...again cash is needed. Amarin has limited options to raise cash with stock due to ANCHOR rescindment. ANCHOR rescindment made the World the FDA’s RWE testing ground, costing Billions in healthcare expenses. It’s not a hard concept to understand....for most.
BB

[ralphey]

If REDUCE IT succeeds then AMRN needs to overcome the DS issue (which I brought up several years ago on other sites and months ago here (which you all said was not an issue ...)) and if they can do that then they will have success in the marketplace and should become profitable

Its a long road ....

1.) Reduce IT fails - stock plummets
2.) Reduce IT succeeds only in select subgroups stock either drops or perhaps remains steady ( would all depend on the loss of Rx currently being written for reduction of CAD for trigs 200- 500 would be supplanted by FDA approval in select sub groups )
3.) REDUCE IT succeeds - still need to overcome DS issue if AMRN can - then success

but still remaining is the major issue which AMRN has not yet detected